AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01557621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Pop-Based R/R: Phone/Mail Group
Description: Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
Study NCT01557621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Pop-Based R/R: Mail-Only Group
Description: Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
Study NCT01557621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice-based Recall
Description: All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
Study NCT00642135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mydriasert®
Description: Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
Study NCT03091192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT04266886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Receive self-hypnosis guided relaxation
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00642135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine and tropicamide eyedrops
Description: Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
Study NCT00423293 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Description: 1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04266886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00423293 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mitomycin C
Description: 10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.
Study NCT00423293 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiation therapy
Description: Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx.
Study NCT01208155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 2, single dose
Study NCT01208155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 1, single dose
Study NCT01208155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 2, single dose
Study NCT01208155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg Batch 3, single dose
Study NCT02357810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT02357810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Topotecan Hydrochloride
Description: Given PO
Study NCT02357810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02761460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
Study NCT01780129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydatin Injectable
Description: Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
Study NCT02007408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block
Study NCT02007408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine spray
Study NCT02007408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block + lidocaine spray
Study NCT03153982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally
Study NCT02826668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
Study NCT02490462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education + Conventional PhysicalTherapy
Description: The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
Study NCT02490462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
Study NCT03495739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDG-17012 Capsule
Description: Dabigatran Etexilate tosylate 150mg
Study NCT03495739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Mesylate 150 MG Oral Capsule
Description: Dabigatran Etexilate mesylate 150mg
Study NCT03934723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
Study NCT03934723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
Study NCT03089697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
Study NCT03089697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
Study NCT00135798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LADR Treatment
Description: PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued.
Study NCT02637895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill matching Vortioxetine.
Study NCT02637895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: Immediate Release 10 mg. Vortioxetine Pill
Study NCT04748458 — intervention group
Intervention type: DEVICE
Intervention: Conical tapered stem
Description: Implantation of conical tapered stem
Study NCT04322019 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT01647516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod capsules by mouth daily.
Study NCT01647516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00920127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AKL1
Description: Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.
Study NCT00920127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AKL1
Description: Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.
Study NCT03586674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipanthyl
Description: Tablet
Study NCT03586674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursogal
Description: suspension
Study NCT03586674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursogal
Description: suspension
Study NCT03109665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT Angiography
Description: SD-OCT Angiography
Study NCT03109665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: SD-OCT
Study NCT01178879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth consultation
Description: The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line.
Study NCT03193801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Description: Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
Study NCT00900549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT on
Description: 12 months
Study NCT00900549 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CRT off
Description: 12-month
Study NCT02188472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin V
Description: Penicillin V: 2 x 330mg tablets should be taken twice daily
Study NCT02188472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: Trimopan: 2 x 100mg tablets should be taken twice daily
Study NCT02188472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 tablets should be taken twice daily
Study NCT02573558 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Study NCT02573558 — intervention group
Intervention type: DRUG
Intervention: Propofol
Study NCT02733354 — intervention group
Intervention type: DEVICE
Intervention: watch viedo
Study NCT00846677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, cholecalciferol
Description: Oral Quick Dissolve Strip, 400 IU once per day for 21 days
Study NCT00846677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D, cholecalciferol
Description: Oral Syrup, 400IU per day for 21 days
Study NCT02659514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: 8 mg oral tablets, administered QD.
Study NCT03417232 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CAF
Description: The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
Study NCT03417232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
Study NCT04174183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-incision Negative-pressure Therapy - Dry dressing
Description: A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
Study NCT00270153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enalapril
Description: 5mg enalapril daily for 6 months
Study NCT00270153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg enalapril-matching placebo daily for 6 months
Study NCT01595464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
Study NCT03697759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + selfBACK
Description: The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient.
Study NCT03592537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
Study NCT03592537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
Study NCT03592537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
Study NCT02409745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle
Study NCT02409745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle
Study NCT04673747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
Study NCT04673747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
Study NCT04673747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual correction of the sacroiliac joint
Description: Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
Study NCT01574638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.